SCHEDULE 13G/A: Fairmount Funds Discloses 9.9% Stake in Astria Therapeutics, Inc. via Latest SEC Filing

Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have reported a combined beneficial ownership of 9.9% in Astria Therapeutics, Inc., totaling 5,869,037 shares, including common stock and exercisable warrants.

Summary

• Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC, collectively referred to as the Reporting Persons, have filed an Amendment No. 6 to Schedule 13G regarding their beneficial ownership in Astria Therapeutics, Inc.
• As of December 31, 2024, the Reporting Persons beneficially own an aggregate of 5,869,037 shares of Astria Therapeutics, Inc. Common Stock.
• This ownership represents 9.9% of Astria Therapeutics, Inc.'s outstanding Common Stock.
• The total beneficial ownership comprises 3,554,129 shares of Common Stock held directly by Fairmount Healthcare Fund II LP ("Fund II").
• Additionally, it includes 650,000 shares that Fund II has the right to acquire through the exercise of pre-funded warrants.
• The ownership also includes 1,664,908 shares that Fund II has the right to acquire through the exercise of common warrants, out of a total of 1,727,049 exercisable common warrants.
• Both the pre-funded warrants and common warrants contain a 'Beneficial Ownership Limitation' provision, which prevents exercise if it would result in the Reporting Person, along with attribution parties, owning more than 9.99% of the Common Stock outstanding.
• The percentage calculation is based on 56,434,219 shares of Astria Therapeutics, Inc. Common Stock outstanding as of October 31, 2024, as disclosed in the Issuer's Form 10-Q filed on November 13, 2024.
• The Reporting Persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would significantly alter the sentiment towards Astria Therapeutics, Inc. It is a routine regulatory filing.

Positives

• The disclosure of a significant institutional stake (9.9%) by Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC may signal confidence from a sophisticated investor in Astria Therapeutics, Inc.

Risks

• No specific risks to Astria Therapeutics, Inc. are detailed in this beneficial ownership filing, as it primarily concerns the reporting of an investor's stake.

Future Outlook

This filing is a beneficial ownership report from an institutional investor and does not contain forward-looking statements or guidance from Astria Therapeutics, Inc. The Reporting Persons have certified that their holdings are not for the purpose of changing or influencing the control of the issuer.

Management Comments

• "The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This Schedule 13G filing is a routine disclosure for institutional investors holding a significant stake in a publicly traded company. It indicates Fairmount Funds' continued substantial investment in Astria Therapeutics, a company operating in the healthcare/biotechnology sector. Such filings provide transparency on major shareholder positions but do not typically offer insights into broader industry trends or competitive dynamics.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, potentially signaling continued confidence in the company's prospects.

Next Steps

• Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC will continue to monitor their investment in Astria Therapeutics, Inc. and may file further amendments to Schedule 13G as their beneficial ownership changes.

Key Dates

Keywords

Astria Therapeutics, Fairmount Funds Management, Fairmount Healthcare Fund, Schedule 13G, beneficial ownership, common stock, warrants, institutional investment, biotechnology, healthcare